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▪Conditional knockout of the IL-1R
receptor in KM-LUAD mouse models
will allow for a greater understanding
of the involvement of the IL-1
cytokine family in tumor promotion
and potentially support the idea of a
new target for treatment.
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▪ IL-1R conditional knockout results
in a significant decrease in tumor
burden as shown by the H&E
staining.
▪ IHC staining indicated a negative
trend in the expression of Ki67
along with ERG, which could mean
the IL-1R conditional knockout
suppressed tumor proliferation and
angiogenesis.
▪ qRT-PCR analysis of RNA
extracted from the lung revealed
an increase in Cd8a expression
along with a significant decrease in
Ym1 expression, which supports
the notion of increased antitumor
cytotoxic activity.
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Future Directions
▪ Repeat qPCR analysis to
confirm results and add
additional markers to gain a
more complete understanding
of the tumor microenvironment.
▪ Stain samples with p65 marker
to evaluate the effects the
conditional knock-out of IL-1R
will have on the NF-kB
pathway.
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▪ As of last year, 23% of cancerrelated deaths have been attributed
to lung cancer. It is the third most
common cause of cancer in males
and females and its low survival
rate has also been an area of
concern with only 26% of diagnosed
patients surviving up to 5 years.
▪ Non-small cell lung cancer (NSCLC)
is the most common type of lung
cancer, in which mutations of the Kras oncogene are the driving factor
leading to the promotion of lung
adenocarcinoma
(LUAD),
a
histological subtype of NSCLC.
▪ Mutations of the K-ras oncogene
have been shown to cause
increased activation of the NF-κB
pathway
and
inflammatory
response, promoting a pro-tumor
microenvironment.
▪ The pro-inflammatory cytokine IL-1β
plays a major role in the activation
of the NF-κB pathway and has been
found in abundance at tumor sites.
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Methods
Animals:

Conditional Knockout of the IL-1 receptor leads to a significant decrease in tumor area. (A) Representative
photomicrographs of the H&E stained whole lung sections from 14 week old CC-LR mice as well as LR/IL-1RΔ/Δ mice
(4X). Representative photomicrographs of the stained IHC sections (20x) and corresponding quantification of (B)
proliferation marker Ki-67 and (C) angiogenesis marker ERG. Data represent mean±SEM; unpaired t-test, *p<0.05.
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Step 2(qPCR):
Used to find the concentration of
desired DNA in our samples of
interest. Fold changes between test
groups and controls were calculated
using the 2–ΔΔCt method.

Step 2

Step 1(H&E and IHC):
H&E staining was used to calculate
tumor area. IHC staining for Ki-67
and ERG markers were performed to
measure
proliferation
and
angiogenesis, respectively.

Conditional
Knockout of the
IL-1 receptor led
to a decrease in
M2 phenotype.
Relative mRNA
expression of
Ym1, CD206,
TNF-a, Gzmb, and
CD8 in the whole
lung. Data
represent
mean±SEM;
unpaired t-test,
*p<0.05.
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